^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Jaypirca (pirtobrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pirtobrutinib in Covalent BTK Inhibitor Pre‑Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow‑Up from Start of Enrollment
Published date:
09/01/2023
Excerpt:
Patients with cBTKi pre-treated R/R MCL received pirtobrutinib monotherapy in a multicenter phase 1/2 BRUIN trial (NCT03740529)....Responses were observed in patients with high-risk disease features, including blastoid/pleomorphic variants, elevated Ki67 index, and TP53 mutations.
Trial ID:
Source:
Title:
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.
Published date:
05/25/2023
Excerpt:
Pts with cBTKi pre-treated R/R MCL received pirtobrutinib monotherapy in a multicenter phase 1/2 BRUIN trial (NCT03740529)….Responses were observed in pts with high-risk disease features including pts with blastoid/pleomorphic variants, elevated Ki67 index, and TP53 mutations.
DOI:
10.1200/JCO.2023.41.16_suppl.7514
Trial ID:
